Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract
Latest news
12 May, 2022
Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections
13 Apr, 2022
Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022
Meet the team
Douglas Thomson
Chief Executive Officer
Dr David Howat
Development Director
Thomas Engelen
Non-executive Chairman
Professor Garry Taylor
Director and Chairman of the Scientific Advisory Board
Mark R. Bamforth
Non-executive Director